-->

HTRF Human Total SMARCA2 Detection Kit HTRF®

The Total SMARCA2 kit is designed to quantify the expression level of SMARCA2 in cells.

See more
  • All inclusive kit All inclusive kit
  • Low sample consumption Low sample consumption
  • No-wash No-wash
  • High sensitivity High sensitivity

The Total SMARCA2 kit is designed to quantify the expression level of SMARCA2 in cells.

-

Overview

The SMARCA subgroup of genes belongs to the SWI/SNF family, involved in chromatin remodeling and DNA damage repair. SWI/SNF complexes regulate the genes involved in essential processes such as DNA replication, damage repair, and cell proliferation.

SMARCA4/BRG1 and SMARCA2/BRM are two mutually exclusive catalytic ATPase subunits of the SWI/SNF complex.

SMARCA4 loss of function is frequently associated with cancer, and a synthetic lethal relationship between SMARCA4 and SMARCA2 is well established in SMARCA4-deficient cancers, where the inactivation of SMARCA2 leads to tumor cell death.

Among therapeutic strategies being investigated to fight cancers, targeted protein degradation is expected to overcome some limitations from conventional small molecules. So far, PROTAC molecules have been developed to induce the selective degradation of SMARCA proteins. However, SMARCA2 and SMARCA4 share about 75% identity at the protein level, and so compounds are likely to target both proteins. Therefore, the selectivity of compounds targeting either SMARCA2 or SMARCA4 must be carefully investigated. In such investigations, the HTRF total SMARCA4 kit is a valuable companion assay for the HTRF total SMARCA2 kit, enabling reliable compound profiling.

Benefits

  • SPECIFICITY
  • PRECISION
  • COMPOUND PROFILING
  • PROTAC

Total-SMARCA2 assay principle

The HTRF Total-SMARCA2 assay quantifies the expression level of SMARCA2 in a cell lysate. Unlike Western Blot, the assay is entirely plate-based and does not require gels, electrophoresis, or transfer. The Total-SMARCA2 assay uses two labeled antibodies: one coupled to a donor fluorophore, the other to an acceptor. Both antibodies are highly specific for a distinct epitope on the protein. In presence of SMARCA2 in a cell extract, the addition of these conjugates brings the donor fluorophore into close proximity with the acceptor, and thereby generates a FRET signal. Its intensity is directly proportional to the concentration of the protein present in the sample, and provides a means of assessing the protein’s expression under a no-wash assay format

Principle of the HTRF total SMARCA2 assay

Total-SMARCA2 two-plate assay protocol

The two-plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates into a 384-well low volume detection plate before the addition of Total-SMARCA2 HTRF detection reagents. This protocol enables the cells' viability and confluence to be monitored.

Two-plate protocol of the HTRF total SMARCA2 assay

Total-SMARCA2 one-plate assay protocol

Detection of Total-SMARCA2 with HTRF reagents can be performed in a single plate used for culturing, stimulation, and lysis. No washing steps are required. This HTS designed protocol enables miniaturization while maintaining robust HTRF quality.

One-plate protocol of the HTRF total SMARCA2 assay

Specificity of HTRF Total SMARCA2 assay using relevant cell lines

SMARCA2 expression levels were assessed with the HTRF total SMARCA2 kit in A549 (lung carcinoma) and in HAP1 cells (WT). In parallel, the expression of SMARCA4 was assessed with HTRF total SMARCA4 kit. Cell density was optimized beforehand to ensure HTRF detection within the dynamic range of the kit (data not shown).

The different cell lines were plated in 96-well culture plates at a density of 200,000 cells/well and incubated for 24 hours at 37°C, 5% CO2. After culture medium removal, the cells were lysed with 50 µL of supplemented lysis buffer #1 (1X) for 30 min at RT under gentle shaking. Then 16 µL of cell lysate were transferred into a low volume white microplate, followed by 4 µL of premixed detection reagents. The HTRF signal was recorded after an overnight incubation at RT.


Low expression of SMARCA2 was detected in A549 cells, whereas SMARCA4 expression was equivalent to the non-specific signal (dotted line), indicating a lack of expression of SMARCA4, as described in the literature (Hoffman, G. R. et al. Proc. Natl Acad. Sci. 2014).

Furthermore, the expression levels of SMARCA2 in HAP1 cells were equivalent to the non-specific signal (dotted line), indicating a lack of expression of SMARCA2, whereas SMARCA4 levels were well detected in the HAP1, as expected.

These results demonstrate the specificity of the HTRF SMARCA2 kit over SMARCA4, despite these two proteins sharing more than 70% sequence homology.

Catalog cell line references (Horizon Discovery): HAP1 Wt #C631.

Specificity of HTRF Total SMARCA2
Specificity of HTRF Total SMARCA4

Validation on various Human cell lines

The adherent Human cell lines HeLa (Cervix), HEK293 (Kidney), and A549 (Lung Carcinoma) were plated in 96-well culture plates at a density of 200,000 cells/well and incubated for 24 hours at 37°C, 5% CO2. After culture medium removal, the cells were lysed with 50 µL of supplemented lysis buffer #1 (1X) for 30 min at RT under gentle shaking.

The suspension Human cell lines HEL92.1.7 (erythroleukemia) and MOLT-4 (T lymphoblastic leukemia) were dispensed under 30 µL in a 96-well plate at a density of 200,000 cells/well, incubated for 1h at 37°C, 5% CO2, and lysed with 10 µL of supplemented lysis buffer #1 (4X) for 30 min at RT under gentle shaking.

The SMARCA2 expression level was assessed with the HTRF Total SMARCA2 kit. Briefly, 16 µL of cell lysate were transferred into a low volume white microplate followed by 4 µL of premixed HTRF detection reagents. The HTRF signal was recorded after an overnight incubation at RT. The dotted line corresponds to the non-specific HTRF signal. Note that the cell density was optimized beforehand to ensure HTRF detection within the dynamic range of the kit (data not shown).

The HTRF Total SMARCA2 assay efficiently detects endogenous SMARCA2 in various cellular models expressing different levels of the protein.

Validation on various cell lines Total SMARCA2 assay

PROTAC® induced SMARCA2 degradation

HEL92.1.7 cells were seeded in a 96-well plate (100,000 cells/30µL well) and treated with increasing concentrations of  PROTAC® compounds ACBI1 and AU-15330, as well as a PROTAC ARV-471 (PROTAC® Estrogen Receptor) used as a negative irrelevant control. After overnight incubation, cells were lysed with 10 µl of supplemented lysis buffer #1 (4X) for 30 min at RT under gentle shaking. After cell lysis, 16 µL of lysates were transferred into a 384-well low volume white microplate and 4 µL of the HTRF total SMARCA2 detection antibodies were added. The HTRF signal was recorded after an overnight incubation.


Cell treatment with the two SMARCA2 PROTAC® degraders triggered a dose-dependent decrease in SMARCA2 protein, while the expression levels of SMARCA2 in the ARV-471 control conditions as well as the ATP levels remained stable. These results suggest a PROTAC® induced specific SMARCA2 degradation, with a DC50* in the nM range, as  expected (Farnabay, W. et al. Nat Chem Biol. 2019 and Xiao, L. et al. Nature 2022).


* DC50  corresponds to the concentration of the degrader at which 50% of the targeted protein is degraded.

Pharmacological validation Total SMARCA2 assay-PROTAC on HEL92.1.7 cells
Pharmacological validation Total SMARCA2 assay- ATPLITE on HEL92.1.7 cells

PROTAC® SMARCA2 versus SMARCA4 profiling

Profiling SMARCA2 versus SMARCA4- Total Assay
Profiling SMARCA2 versus SMARCA4- Total SMARCA2

HEL92.1.7 cells were seeded in a 96-well plate (100,000 cells/ 30µL well) and treated with increasing concentrations of  PROTAC® compounds ACBI1 and AU-15330. After overnight incubation, cells were lysed with 10 µl of supplemented lysis buffer #1 (4X) for 30 min at RT under gentle shaking. After cell lysis, 16 µL of lysates were transferred into a 384-well low volume white microplate and 4 µL of the HTRF detection antibodies were added, using Total SMARCA2 or Total SMARCA4 assay reagents. The HTRF signal was recorded after an overnight incubation

The results indicate an ACBI1 and AU-15330 induced dose-dependent SMARCA2 and SMARCA4 decrease. ATP levels remained stable in the same conditions (data not shown). These results are consistent with studies from Farnabay, W. et al. (Nat Chem Biol. 2019) and Xiao, L. et al. (Nature 2022).


PROTAC®Described protein targetsE3L ligandsDC50 (nM)



Total SMARCA2Total SMARCA4
ACBI1SMARCA2 & SMARCA4 &PBRM1VHL Ligand224231
AU-15330SMARCA2 & SMARCA4 &PBRM1VHL Ligand242620

HTRF total SMARCA2 assay compared to Western Blot

HEL92.1.7 cells were cultured in a T175 flask in complete culture medium at 37°C, 5% CO2. After a 24h incubation followed by cell medium removal, the cells were lysed with 3 mL of supplemented lysis buffer #1 (1X) for 30 minutes at RT under gentle shaking.

Serial dilutions of the cell lysate were performed using supplemented lysis buffer#1, and 16 µL of each dilution were transferred into a low volume white microplate before the addition of 4 µL of HTRF total SMARCA2 detection reagents.

Equal amounts of lysates were used for a side-by-side comparison between HTRF and Western Blot.


In these conditions, the HTRF total SMARCA2 assay was as sensitive as the Western Blot technique.

HTRF total SMARCA2 assay compared to Western Blot

SMARCA2 Signaling Pathway

SMARCA2 and SMARCA4 are catalytic subunits within the SWI/SNF complex involved in DNA transcription and repair. SMARCA2 and SMARCA4 comprise 6 different domains, including a DNA-dependent ATPase domain and a Bromo domain. The Bromo domain and H3K27 acetylated levels regulate the binding between DNA and the SWI/SNF complex, while the ATPase domain catalyzes the separation of the two DNA strands. These functions are counteracted by the EZH2 catalytic subunit of the PRC2 complex repressing gene transcription. The loss of function of SMARCA2 or SMARCA4 leads to increased DNA damage, as PRC2 continues to bind to the nucleosome and inhibit DNA repair.

SMARCA2 signaling pathway

HTRF cellular phospho-protein assays

Physiologically relevant results fo fast flowing research - Flyers

Best practices for analyzing brain samples with HTRF® phospho assays for neurosciences

Insider Tips for successful sample treatment - Technical Notes

Optimize your HTRF cell signaling assays on tissues

HTRF and WB compatible guidelines - Technical Notes

Best practices for analyzing tumor xenografts with HTRF phospho assays

Protocol for tumor xenograft analysis with HTRF - Technical Notes

Key guidelines to successful cell signaling experiments

Mastering the art of cell signaling assays optimization - Guides

HTRF® cell signaling platform combined with iCell® Hepatocytes

A solution for phospho-protein analysis in metabolic disorders - Posters

HTRF phospho-assays reveal subtle drug-induced effects

Detailed protocol and direct comparison with WB - Posters

Universal HTRF® phospho-protein platform: from 2D, 3D, primary cells to patient derived tumor cells

Analysis of a large panel of diverse biological samples and cellular models - Posters

HTRF cell-based phospho-protein data normalization

Valuable guidelines for efficiently analyzing and interpreting results - Application Notes

HTRF phospho-total lysis buffer: a universal alternative to RIPA lysis buffers

Increased flexibility of phospho-assays - Application Notes

HTRF Alpha-tubulin Housekeeping kit

Properly interpret your compound effect - Application Notes

Simplified pathway dissection with HTRF phospho-assays and CyBi-felix liquid handling

Analyse of PI3K/AKT/mTor translational control pathway - Application Notes

How to run a cell based phospho HTRF assay

What to expect at the bench - Videos

Unleash the potential of your phosphorylation research with HTRF

A fun video introducing you to phosphorylation assays with HTRF - Videos

How to run a cell based phospho HTRF assay

3' video to set up your Phospho assay - Videos

Methodological Aspects of Homogeneous Time-Resolved Fluorescence (HTRF)

Learn how to reduce time and sample consumption - Application Notes

Assessment of drug efficacy and toxicity by combining innovative technologies

Combination of AlphaLISA®, HTRF®, or AlphaLISA® SureFire® Ultra™ immunoassays with the ATPlite™ 1step cell viability assay - Application Notes

HTRF phospho assays reveal subtle drug induced effects in tumor-xenografts

Tumor xenograft analysis: HTRF versus Western blot - Application Notes

Guidelines for Cell Culture and Lysis in Different Formats Prior to HTRF Detection

Seeding and lysing recommendations for a number of cell culture vessels. - Technical Notes

Product Insert Smarca2 Total Kit / 64SMARC2TPEG-64SMARC2TPEH

64SMARC2TPEG-64SMARC2TPEH - Product Insert

Plate Reader Requirement

Choosing the right microplate reader ensures you’ll get an optimal readout. Discover our high performance reader, or verify if your lab equipment is going to be compatible with this detection technology.

Let's find your reader